CDK4 and non-small cell lung carcinoma: Here, we describe a patient with newly diagnosed metastatic NSCLC with a common EGFR mutation, a PIK3CA mutation and CDK4 amplification, who benefited from combined osimertinib and palbociclib treatment after disease progression on treatment with osimertinib alone.